Your browser doesn't support javascript.
loading
H3K79me2/3 controls enhancer-promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells.
Godfrey, Laura; Crump, Nicholas T; O'Byrne, Sorcha; Lau, I-Jun; Rice, Siobhan; Harman, Joe R; Jackson, Thomas; Elliott, Natalina; Buck, Gemma; Connor, Christopher; Thorne, Ross; Knapp, David J H F; Heidenreich, Olaf; Vyas, Paresh; Menendez, Pablo; Inglott, Sarah; Ancliff, Philip; Geng, Huimin; Roberts, Irene; Roy, Anindita; Milne, Thomas A.
Afiliação
  • Godfrey L; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Crump NT; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • O'Byrne S; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Lau IJ; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Rice S; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Harman JR; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Jackson T; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Elliott N; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Buck G; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Connor C; Great Ormond Street Hospital for Children, London, UK.
  • Thorne R; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Knapp DJHF; MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Heidenreich O; Princess Maxima Centrum for Pediatric Oncology, Utrecht, The Netherlands.
  • Vyas P; Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle upon Tyne, UK.
  • Menendez P; MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR Oxford Biomedical Research Centre Haematology Theme, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
  • Inglott S; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Ancliff P; Josep Carreras Leukemia Research Institute, Barcelona, Spain.
  • Geng H; Institucio Catalana of Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  • Roberts I; Centro de Investigación Biomédica en Red en cancer (CIBERONC)-ISCIII, Barcelona, Spain.
  • Roy A; Great Ormond Street Hospital for Children, London, UK.
  • Milne TA; Great Ormond Street Hospital for Children, London, UK.
Leukemia ; 35(1): 90-106, 2021 01.
Article em En | MEDLINE | ID: mdl-32242051
ABSTRACT
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The most common MLLr produces an MLL-AF4 fusion protein. MLL-AF4 promotes leukemogenesis by activating key target genes, mainly through recruitment of DOT1L and increased histone H3 lysine-79 methylation (H3K79me2/3). One key MLL-AF4 target gene is PROM1, which encodes CD133 (Prominin-1). CD133 is a pentaspan transmembrane glycoprotein that represents a potential pan-cancer target as it is found on multiple cancer stem cells. Here we demonstrate that aberrant PROM1/CD133 expression is essential for leukemic cell growth, mediated by direct binding of MLL-AF4. Activation is controlled by an intragenic H3K79me2/3 enhancer element (KEE) leading to increased enhancer-promoter interactions between PROM1 and the nearby gene TAPT1. This dual locus regulation is reflected in a strong correlation of expression in leukemia. We find that in PROM1/CD133 non-expressing cells, the PROM1 locus is repressed by polycomb repressive complex 2 (PRC2) binding, associated with reduced expression of TAPT1, partially due to loss of interactions with the PROM1 locus. Together, these results provide the first detailed analysis of PROM1/CD133 regulation that explains CD133 expression in MLLr ALL.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Histonas / Regulação Leucêmica da Expressão Gênica / Proteínas de Fusão Oncogênica / Elementos Facilitadores Genéticos / Regiões Promotoras Genéticas / Proteína de Leucina Linfoide-Mieloide / Antígeno AC133 Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células-Tronco Neoplásicas / Histonas / Regulação Leucêmica da Expressão Gênica / Proteínas de Fusão Oncogênica / Elementos Facilitadores Genéticos / Regiões Promotoras Genéticas / Proteína de Leucina Linfoide-Mieloide / Antígeno AC133 Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido